
  
    
      
        Background_NNP
        Due_JJ to_TO the_DT current_JJ unavailability_NN of_IN anti-_NN HIV_NNP vaccines_NNS ,_,
        other_JJ preventive_JJ methods_NNS have_VBP to_TO be_VB developed_VBN to_TO control_VB
        the_DT ongoing_JJ AIDS_NNP pandemic_JJ ._. This_DT includes_VBZ the_DT design_NN and_CC
        application_NN of_IN safe_JJ and_CC effective_JJ topical_JJ microbicides_NNS ._.
        Screening_NNP of_IN pharmaceutical_JJ excipients_NNS revealed_VBD that_DT
        cellulose_NN acetate_NN phthalate_NN (_( CAP_NNP )_) ,_, commonly_RB used_VBN for_IN
        enteric_JJ coating_NN of_IN tablets_NNS and_CC capsules_NNS [_NN 1_CD ]_NN ,_, has_VBZ
        anti-_NN HIV-_NNP 1_CD activity_NN ._. CAP_NNP in_IN micronized_JJ form_NN and_CC formulated_VBN
        into_IN a_DT cream_NN ,_, is_VBZ a_DT broad_JJ spectrum_NN microbicide_NN inactivating_VBG
        several_JJ sexually_RB transmitted_VBD disease_NN (_( STD_NNP )_) pathogens_NNS [_NN 2_CD 3_CD
        4_CD ]_NN ,_, including_VBG HIV-_NNP 1_CD [_NN 2_CD 5_CD ]_NN ._. It_PRP was_VBD of_IN interest_NN to_TO
        explore_VB the_DT mechanism_NN (_( s_VBZ )_) whereby_WRB CAP_NNP causes_NNS inactivation_NN of_IN
        HIV-_NNP 1_CD ._. Since_IN CAP_NNP has_VBZ a_DT relatively_RB high_JJ molecular_JJ weight_NN (_( M_NNP 
        w_NN ~_NN 60_CD ,_, 000_CD ;_: [_NN 2_CD ]_NN )_) ,_, its_PRP$ effect_NN on_IN HIV-_NNP 1_CD
        virions_NNS would_MD be_VB expected_VBN to_TO be_VB confined_VBN to_TO the_DT virus_NN
        surface_NN ,_, i_NNP ._. e_SYM ._. to_TO the_DT envelope_NN glycoproteins_NNS gp_NN 120_CD and_CC /_NN or_CC
        gp_NN 41_CD ._. Thus_RB ,_, CAP_NNP would_MD be_VB expected_VBN to_TO affect_VB one_CD or_CC more_JJR
        steps_NNS required_VBN for_IN HIV-_NNP 1_CD entry_NN into_IN cells_NNS ,_, i_NNP ._. e_SYM ._. binding_JJ to_TO
        cellular_JJ CD_NNP 4_CD ,_, to_TO the_DT major_JJ HIV-_NNP 1_CD coreceptors_NNS CXCR_NNP 4_CD or_CC CCR_NNP 5_CD
        for_IN X_NNP 4_CD and_CC R_NN 5_CD viruses_NNS [_NN 6_CD ]_NN ,_, respectively_RB ,_, and_CC fusion_NN with_IN
        cell_NN membranes_NNS [_NN 7_CD 8_CD 9_CD 10_CD 11_CD 12_CD 13_CD 14_CD 15_CD ]_NN ._. Results_NNS
        presented_VBN here_RB show_NN that_IN CAP_NNP pretreated_JJ HIV-_NNP 1_CD has_VBZ a_DT reduced_VBN
        capacity_NN to_TO bind_NN to_TO the_DT coreceptors_NNS leading_VBG to_TO impaired_VBN
        virus_NN infectivity_NN ._.
      
      
        Methods_NNP
        
          Reagents_NNP
          The_DT following_VBG monoclonal_NN antibodies_NNS (_( mAbs_NNS ;_: the_DT source_NN
          is_VBZ indicated_VBN in_IN parentheses_NNS )_) were_VBD used_VBN :_: 2_CD F_NN 5_CD and_CC 588_CD D_NNP
          (_( Drs_NNP ._. T_NN ._. Muster_NNP and_CC S_NNP ._. Zola-_NNP Pazner_NNP ,_, respectively_RB )_) ;_: 9305_CD
          and_CC 9284_CD (_( NEN_NNP Research_NNP Products_NNPS ,_, Du_NNP Pont_NNP ,_, Boston_NNP ,_, MA_NNP )_) ;_:
          b_SYM 12_CD ,_, 2_CD G_NNP 12_CD and_CC 17_CD b_SYM (_( AIDS_NNP Research_NNP and_CC Reference_NNP Reagent_NNP
          Program_NNP ,_, Rockville_NNP ,_, MD_NNP ;_: courtesy_NN of_IN Drs_NNP ._. D_NNP ._. Burton_NNP ,_, H_NNP ._.
          Katinger_NNP and_CC J_NNP ._. E_NNP ._. Robinson_NNP ,_, respectively_RB )_) and_CC anti-p_JJ 24_CD
          (_( ImmunoDiagnostics_NNP ,_, Inc_NNP ._. ,_, Woburn_NNP ,_, MA_NNP )_) ._. Rabbit_NNP antibodies_NNS
          against_IN peptides_NNS from_IN HIV-_NNP 1_CD IIIB_NNP gp_NN 120_CD /_NN gp_NN 41_CD and_CC against_IN
          the_DT V_NNP 3_CD loop_NN of_IN HIV-_NNP 1_CD BaL_NNP (_( anti-_NN V_NNP 3_CD BaL_NNP )_) were_VBD prepared_VBN as_IN
          described_VBN [_NN 16_CD ]_NN ._. Antiserum_NNP to_TO phthalate_NN was_VBD prepared_VBN by_IN
          immunization_NN of_IN rabbits_NNS with_IN phthalic_JJ anhydride_NN treated_VBD
          rabbit_NN serum_NN albumin_NN [_NN 17_CD ]_NN ._. Recombinant_NNP soluble_JJ CD_NNP 4_CD
          (_( sCD_NN 4_LS )_) was_VBD from_IN Genentech_NNP Inc_NNP ._. ,_, South_NNP San_NNP Francisco_NNP ,_, CA_NNP ._.
          Recombinant_NNP HIV-_NNP 1_CD IIIB_NNP and_CC MN_NNP gp_NN 120_CD ,_, biotinylated_JJ gp_NN 120_CD
          and_CC biotinylated_JJ sCD_NN 4_CD were_VBD from_IN ImmunoDiagnostics_NNP Inc_NNP ._.
          Protein_NNP A_DT ,_, the_DT protease_NN inhibitors_NNS phenylmethyl-sulfonyl_JJ
          fluoride_NN ,_, leupeptin_NN and_CC pepstatin_NN ,_, and_CC 2_CD ,_, 3_CD -_: bis_NNS
          [_NN 2_CD -_: methoxy-_NN 4_CD -_: nitro-_NN 5_CD -_: sulfophenyl_NN ]_NN -_: 2_CD H-_NNP tetrazolium-_NN 5_CD -_: carboxanilide_NN
          (_( XTT_NNP )_) were_VBD all_DT from_IN Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP ._. Pelletted_NNP ,_,
          1000_CD -_: fold_VB concentrates_VBZ of_IN HIV-_NNP 1_CD IIIB_NNP (_( 6_CD ._. 8_CD ×_NN 10_CD 10_CD virus_NN
          particles_NNS /_NN ml_NN )_) and_CC BaL_NNP (_( 1_CD ._. 8_CD ×_NN 10_CD 10_CD virus_NN particles_NNS /_NN ml_NN )_)
          were_VBD from_IN Advanced_NNP Biotechnologies_NNP Inc_NNP ._. ,_, Columbia_NNP ,_, MD_NNP ._.
          Chicken_NN serum_NN was_VBD from_IN OEM_NNP Concepts_NNP ,_, Toms_NNP River_NNP ,_, NJ_NNP ._.
          Horseradish_NNP peroxidase_NN (_( HRP_NNP )_) -_: and_CC phycoerythrin_NN
          (_( PE_NNP )_) -_: labeled_VBN streptavidin_NN were_VBD from_IN Amersham_NNP ,_, Arlington_NNP
          Heights_NNP ,_, IL_NNP and_CC R_NN &_CC D_NNP Systems_NNPS ,_, Minneapolis_NNP ,_, MN_NNP ,_,
          respectively_RB ._. HRP_NNP was_VBD quantitated_JJ using_VBG a_DT kit_NN from_IN
          Kirkegaard_NNP and_CC Perry_NNP Laboratories_NNPS Inc_NNP ._. ,_, Gaithersburg_NNP ,_, MD_NNP ._.
          Enzyme_NNP linked_VBD immunoassays_NNS (_( ELISA_NNP )_) kits_NNS for_IN the_DT HIV-_NNP 1_CD p_NN 24_CD
          antigen_NN and_CC for_IN the_DT β-gal_JJ protein_NN were_VBD from_IN Coulter_NNP
          Immunology_NNP ,_, Hialeah_NNP ,_, FL_NNP and_CC 5_CD Prime_NNP →_NN 3_CD Prime_NNP Inc_NNP ._. ,_,
          Boulder_NNP ,_, CO_NNP ._. CAP_NNP was_VBD a_DT gift_NN from_IN Eastman_NNP ,_, Kingsport_NNP ,_, TN_NNP ._.
          H_NNP 9_CD cells_NNS chronically_RB infected_VBN with_IN HIV-_NNP 1_CD IIIB_NNP ,_,
          HeLa-CD_NNP 4_CD -_: LTR-β-gal_NNP cells_NNS ,_, GHOST_NNP CXCR_NNP 4_CD and_CC CCR_NNP 5_CD cells_NNS and_CC
          PM_NNP 1_CD cells_NNS were_VBD obtained_VBN from_IN the_DT AIDS_NNP Research_NNP and_CC
          Reference_NNP Reagent_NNP Program_NN contributed_VBN by_IN Drs_NNP ._. R_NN ._. Gallo_NNP ,_,
          M_NNP ._. Emerman_NNP ,_, D_NNP ._. Littman_NNP ,_, P_NN ._. Lusso_NNP and_CC M_NNP ._. Reitz_NNP ,_,
          respectively_RB ._. The_DT Centricon_NNP centrifugal_JJ ultrafiltration_NN
          devices_NNS were_VBD from_IN Amicon_NNP /_NN Millipore_NNP ,_, Bedford_NNP ,_, MA_NNP ._.
        
        
          Measurement_NNP of_IN HIV-_NNP 1_CD infectivity_NN
          Serial_JJ two-fold_JJ dilutions_NNS of_IN CAP_NNP treated_VBD and_CC untreated_JJ
          HIV-_NNP 1_CD IIIB_NNP (_( undiluted_JJ to_TO 1_CD /_NN 512_CD )_) in_IN RPMI-_NNP 1640_CD medium_NN
          containing_VBG 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NNP )_) were_VBD mixed_VBN with_IN
          MT-_NNP 2_CD cells_NNS (_( 10_CD 4_CD cells_NNS /_NN well_RB )_) and_CC placed_VBN into_IN 96_CD -_: well_RB
          polystyrene_NN plates_NNS ._. The_DT mixtures_NNS were_VBD incubated_JJ for_IN 1_CD h_NN
          at_IN 37_CD °_NN C_NNP and_CC the_DT volume_NN was_VBD adjusted_VBN with_IN RPMI-_NNP 1640_CD medium_NN
          containing_VBG 10_CD %_NN FBS_NNP to_TO 200_CD μl_NN ._. On_IN the_DT 4_CD thand_NN 6_CD thday_NN
          after_IN incubation_NN at_IN 37_CD °_NN C_NNP ,_, 100_CD μl_NN of_IN culture_NN supernatants_NNS
          were_VBD removed_VBN from_IN each_DT well_RB and_CC equal_JJ volumes_NNS of_IN fresh_JJ
          medium_NN were_VBD added_VBN ._. On_IN the_DT 6_CD thday_NN ,_, XTT_NNP dye_NN (_( 1_CD mg_NN /_NN ml_NN )_) was_VBD
          added_VBN to_TO the_DT cells_NNS ,_, Intracellular_NNP formazan_NN was_VBD determined_VBN
          spectrophotometrically_RB [_NN 18_CD 19_CD ]_NN ._. Similar_JJ experiments_NNS
          were_VBD done_VBN with_IN HIV-_NNP 1_CD BaL_NNP ,_, except_IN that_DT PM_NNP 1_CD cells_NNS were_VBD used_VBN
          instead_RB of_IN MT-_NNP 2_CD cells_NNS ,_, and_CC virus_NN production_NN was_VBD measured_VBN
          by_IN ELISA_NNP for_IN p_NN 24_CD antigen_NN one_CD week_NN after_IN infection_NN ._. The_DT
          percentage_NN of_IN residual_JJ infectivity_NN after_IN CAP_NNP treatment_NN
          was_VBD calculated_VBN from_IN calibration_NN curves_NNS relating_VBG
          absorbance_NN (_( corresponding_JJ to_TO formazan_NN for_IN HIV-_NNP 1_CD IIIB_NNP and_CC
          p_NN 24_CD antigen_NN for_IN HIV-_NNP 1_CD BaL_NNP ,_, respectively_RB )_) to_TO virus_NN
          dilutions_NNS of_IN untreated_JJ viruses_NNS ._. The_DT results_NNS were_VBD plotted_VBD
          in_IN Fig_NNP ._. 1_LS ._.
        
        
          Enzyme-linked_NNP immunosorbent_NN assays_NNS (_( ELISA_NNP )_)
          For_IN virus_NN capture_NN assays_NNS ,_, wells_NNS of_IN 96_CD -_: well_RB polystyrene_NN
          plates_NNS (_( Immulon_NNP II_NNP ;_: Dynatech_NNP Laboratories_NNPS Inc_NNP ._. ,_,
          Chantilly_NNP ,_, VA_NNP )_) were_VBD coated_VBN either_CC with_IN sCD_NN 4_CD (_( 1_CD μg_NN /_NN well_RB )_)
          or_CC with_IN monoclonal_NN or_CC polyclonal_NN antibodies_NNS ._. For_IN coating_NN
          with_IN antibodies_NNS ,_, wells_NNS were_VBD first_JJ coated_VBN with_IN protein_NN A_DT
          (_( 1_CD μg_NN /_NN well_RB )_) in_IN 0_CD ._. 1_CD M_NNP Tris_NNP buffer_NN ,_, pH_NN 8_CD ._. 8_CD for_IN 2_CD h_NN at_IN 20_CD °_NN C_NNP
          followed_VBN by_IN either_DT mAbs_NNS (_( 1_CD μg_NN /_NN well_RB )_) or_CC rabbit_NN antisera_NN
          diluted_VBD 1_CD :_: 100_CD in_IN phosphate_NN buffered_JJ saline_NN (_( PBS_NNP )_) for_IN 1_CD h_NN
          at_IN 20_CD °_NN C_NNP ._. Subsequently_RB ,_, the_DT wells_NNS were_VBD washed_VBN and_CC
          postcoated_JJ for_IN 1_CD h_NN at_IN 20_CD °_NN C_NNP with_IN bovine_JJ serum_NN albumin_NN
          (_( BSA_NNP )_) and_CC gelatin_NN (_( 1_CD and_CC 0_CD ._. 1_CD mg_NN /_NN ml_NN in_IN 0_CD ._. 14_CD M_NNP NaCI_NNP ,_, 0_CD ._. 01_CD M_NNP
          Tris_NNP ,_, pH_NN 7_CD ._. 0_CD [_NN TS_NNP ]_NN )_) ._. Chicken_NN serum_NN (_( 10_CD %_NN )_) in_IN PBS_NNP (_( Ch-_NNP PBS_NNP )_)
          was_VBD used_VBN instead_RB in_IN experiments_NNS with_IN HIV-_NNP 1_CD BaL_NNP ._. The_DT wells_NNS
          were_VBD washed_VBN with_IN TS_NNP and_CC stored_VBD at_IN 4_CD °_NN C_NNP ._. HIV-_NNP 1_CD virus_NN
          particles_NNS suspended_VBN in_IN PBS_NNP were_VBD added_VBN to_TO the_DT wells_NNS for_IN 5_CD
          h_NN at_IN 4_CD °_NN C_NNP ._. Subsequently_RB ,_, the_DT wells_NNS were_VBD washed_VBN 10_CD ×_NN with_IN
          ice_NN cold_JJ PBS_NNP or_CC 1_CD :_: 50_CD anti-p_JJ 24_CD mAb_NN in_IN Ch-_NNP PBS_NNP for_IN HIV-_NNP 1_CD
          BaL_NNP ,_, and_CC then_RB treated_VBN with_IN lysis_NNS buffer_NN (_( 1_CD %_NN Nonidet_NNP P_NN 40_CD
          [_NN NP_NNP 40_CD ]_NN ,_, 100_CD μg_NN /_NN ml_NN BSA_NNP in_IN PBS_NNP )_) for_IN 30_CD min_NN at_IN 37_CD °_NN C_NNP ._. The_DT
          supernatants_NNS were_VBD removed_VBN and_CC tested_VBN for_IN p_NN 24_CD antigen_NN
          using_VBG ELISA_NNP kits_NNS from_IN Coulter_NNP Immunology_NNP and_CC following_VBG
          the_DT manufacturer_NN 's_POS protocol_NN ._. In_IN other_JJ experiments_NNS ,_, wells_NNS
          were_VBD coated_VBN with_IN CAP_NNP (_( 1_CD μg_NN /_NN ml_NN )_) in_IN 25_CD mM_NN sodium_NN acetate_NN ,_,
          pH_NN 6_CD ._. 0_CD and_CC postcoated_JJ as_IN described_VBN above_IN ._.
          To_TO detect_VB binding_JJ of_IN CD_NNP 4_CD to_TO CAP_NNP treated_VBD and_CC control_NN
          gp_NN 120_CD ,_, wells_NNS coated_VBN with_IN graded_JJ amounts_NNS of_IN gp_NN 120_CD and_CC
          postcoated_JJ as_IN described_VBN above_IN were_VBD reacted_VBN with_IN
          biotinylated_JJ sCD_NN 4_CD (_( 1_CD μg_NN /_NN well_RB )_) in_IN PBS_NNP containing_VBG 100_CD μg_NN /_NN ml_NN
          BSA_NNP for_IN 18_CD h_NN at_IN 4_CD °_NN C_NNP ,_, washed_VBN with_IN TS_NNP and_CC the_DT bound_VBN
          biotinylated_JJ CD_NNP 4_CD was_VBD determined_VBN after_IN adding_VBG
          HRP-streptavidin_NNP (_( 1_CD μg_NN /_NN ml_NN )_) in_IN TS_NNP containing_VBG 0_CD ._. 25_CD %_NN
          gelatine_NN and_CC 0_CD ._. 05_CD %_NN Tween_NNP 20_CD for_IN 30_CD min_NN at_IN 37_CD °_NN C_NNP ._. The_DT wells_NNS
          were_VBD washed_VBN and_CC bound_VBN HRP_NNP was_VBD detected_VBN using_VBG the_DT test_NN kit_NN
          from_IN Kirkegaard_NNP and_CC Perry_NNP and_CC the_DT absorbance_NN read_NN at_IN 450_CD
          nm_NN ._.
        
        
          Flow_NNP cytometry_NN
          To_TO determine_VB the_DT binding_JJ of_IN gp_NN 120_CD -_: biotinylated_JJ CD_NNP 4_CD
          complexes_NNS to_TO HIV-_NNP 1_CD coreceptor_NN expressing_VBG cells_NNS ,_, CAP_NNP
          treated_VBD and_CC untreated_JJ gp_NN 120_CD (_( 5_CD μg_NN )_) and_CC biotinylated_JJ CD_NNP 4_CD
          (_( 2_CD ._. 5_LS μg_NN )_) in_IN PBS_NNP containing_VBG 100_CD μg_NN /_NN ml_NN of_IN BSA_NNP were_VBD mixed_JJ
          for_IN 1_CD h_NN at_IN 20_CD °_NN C_NNP and_CC then_RB added_VBD to_TO 10_CD 6_CD MT-_NNP 2_CD cells_NNS in_IN
          RPMI-_NNP 1640_CD medium_NN containing_VBG 100_CD μg_NN /_NN ml_NN of_IN BSA_NNP ._.
          Biotinylated_NNP CD_NNP 4_CD -_: gp_NN 120_CD complexes_NNS were_VBD not_RB added_VBN to_TO
          control_VB cells_NNS ._. After_IN 30_CD min_NN at_IN room_NN temperature_NN ,_, the_DT
          cells_NNS were_VBD washed_VBN 3_CD times_NNS with_IN PBS_NNP containing_VBG 100_CD μg_NN /_NN ml_NN
          of_IN BSA_NNP ,_, and_CC PE-streptavidin_NNP (_( 0_CD ._. 1_LS μg_NN )_) was_VBD added_VBN ._. After_IN 20_CD
          min_NN at_IN 20_CD °_NN C_NNP ,_, cells_NNS were_VBD washed_VBN and_CC fixed_VBN in_IN 1_CD %_NN
          formaldehyde_NN in_IN PBS_NNP ._. Flow_NNP cytometry_NN analysis_NN was_VBD
          performed_VBN in_IN a_DT FACSCalibur_NNP flow_NN cytometer_NN (_( Becton_NNP
          Dickinson_NNP Immunocytometric_NNP Systems_NNPS ,_, San_NNP Jose_NNP ,_, CA_NNP )_) ._.
          Similar_JJ experiments_NNS were_VBD done_VBN with_IN peripheral_JJ blood_NN
          lymphocytes_NNS (_( PBL_NNP )_) isolated_VBN by_IN the_DT Isopaque-_NNP Ficoll_NNP
          technique_NN [_NN 20_CD ]_NN ._.
        
        
          Quantitation_NNP of_IN CAP-gp_NNP 120_CD binding_JJ
          Forty_CD μg_NN of_IN gp_NN 120_CD were_VBD mixed_VBN with_IN 40_CD μg_NN of_IN CAP_NNP in_IN 1_CD ml_NN
          TS_NNP or_CC 1_CD M_NNP NaCI_NNP ,_, 0_CD ._. 01_CD M_NNP Tris_NNP ,_, pH_NN 7_CD ._. 0_CD and_CC incubated_JJ at_IN 20_CD °_NN C_NNP
          for_IN 30_CD min_NN ._. The_DT mixtures_NNS were_VBD transferred_VBN into_IN a_DT
          Centricon_NNP centrifugal_JJ ultrafiltration_NN device_NN with_IN a_DT M_NNP 
          w_NN cut-off_JJ of_IN 100_CD ,_, 000_CD and_CC centrifuged_JJ
          at_IN 3_CD ,_, 500_CD ×_NN g_SYM for_IN 30_CD min_NN ._. The_DT filtrates_NNS were_VBD transferred_VBN
          to_TO a_DT similar_JJ device_NN with_IN a_DT M_NNP 
          w_NN cut-off_JJ of_IN 50_CD ,_, 000_CD and_CC centrifuged_JJ
          under_IN the_DT same_JJ conditions_NNS ._. CAP_NNP retained_VBD on_IN top_NN of_IN the_DT
          filter_NN was_VBD quantitated_JJ as_IN a_DT complex_NN with_IN ruthenium_NN red_JJ [_NN
          21_CD ]_NN ._. The_DT retentate_NN on_IN the_DT 100_CD ,_, 000_CD M_NNP 
          w_NN cut-off_JJ filter_NN was_VBD dissolved_VBN in_IN 1_CD ml_NN
          of_IN 2_CD M_NNP guanidinium_NN hydrochloride_NN and_CC CAP_NNP released_VBD from_IN
          the_DT CAP-gp_NNP 120_CD complex_JJ and_CC retained_VBD on_IN the_DT 50_CD ,_, 000_CD M_NNP 
          w_NN cut-off_JJ filter_NN was_VBD quantitated_JJ by_IN
          the_DT same_JJ method_NN ._.
        
        
          Molecular_NNP Modeling_NNP
          A_DT cellulose_NN chain_NN consisting_VBG of_IN one_CD cellotetraose_NN unit_NN
          (_( composed_VBN of_IN four_CD 1_CD ,_, 4_CD -_: linked_VBN β-_NN D-_NNP glucose_NN units_NNS )_) was_VBD
          created_VBN in_IN Quanta_NNP [_NN 22_CD ]_NN and_CC 50_CD %_NN of_IN the_DT hydroxyl_NN groups_NNS
          at_IN positions_NNS 2_CD -_: and_CC 3_CD -_: were_VBD modified_VBN to_TO acetyl_NN ester_NN and_CC
          25_CD %_NN of_IN the_DT hydroxyl_NN groups_NNS at_IN position_NN 6_CD were_VBD modified_VBN to_TO
          phthaloyl_NN ester_NN [_NN 1_CD 23_CD ]_NN ._. The_DT acetylated_JJ and_CC
          phthaloylated_JJ cellotetraose_NN structure_NN (_( CTAP_NNP )_) was_VBD
          minimized_VBN by_IN the_DT steepest_JJS descent_NN method_NN followed_VBN by_IN the_DT
          adopted_VBN basis_NN Newton-_NNP Raphson_NNP (_( ABNR_NNP )_) method_NN ._. The_DT energy_NN
          change_NN of_IN 0_CD ._. 05_CD Kcal_NNP /_NN mol_NN between_IN two_CD successive_JJ structures_NNS
          was_VBD used_VBN as_IN the_DT termination_NN criterion_NN in_IN both_DT the_DT
          steps_NNS ._.
          The_DT crystal_NN structure_NN of_IN gp_NN 120_CD (_( 1_CD gcl_NN )_) [_NN 13_CD ]_NN was_VBD
          retrieved_VBN from_IN the_DT pdb_NN (_( http_NN :_: /_NN /_NN www_NN ._. rcsb_NN ._. org_NN )_) and_CC the_DT V_NNP 3_CD
          loop_NN ,_, created_VBN by_IN homology_NN modeling_NN {_( (_( based_VBN on_IN the_DT nmr_NN
          structure_NN of_IN the_DT V_NNP 3_CD loop_NN from_IN 1_CD ce_NN 4_LS )_) using_VBG the_DT SWISS-MODEL_NNP
          [_NN 24_CD ]_NN automated_VBN comparative_JJ protein_NN modeling_NN server_NN (_(
          http_NN :_: /_NN /_NN www_NN ._. expasy_NN ._. ch_NN /_NN SWISS-MODEL_NNP ._. html_NN }_) was_VBD attached_VBN to_TO
          the_DT gp_NN 120_CD crystal_NN structure_NN using_VBG Quanta_NNP 's_POS protein_NN design_NN
          module_NN ._.
          The_DT docking_VBG simulation_NN of_IN CTAP_NNP onto_IN the_DT entire_JJ gp_NN 120_CD
          protein_NN surface_NN was_VBD performed_VBN by_IN the_DT Dockvision_NNP program_NN [_NN
          25_CD ]_NN ._. A_DT grid_NN box_NN (_( 125_CD Å_NN ×_NN 125_CD Å_NN ×_NN 125_CD Å_NN )_) with_IN grid_NN
          stepsize_NN of_IN 0_CD ._. 5_CD Å_NN was_VBD created_VBN to_TO cover_VB the_DT entire_JJ protein_NN
          surface_NN with_IN enough_JJ area_NN for_IN the_DT ligand_NN to_TO dock_NN ._. The_DT
          default_NN forcefield_NN (_( Research_NNP Potential_JJ Function_NNP )_) was_VBD used_VBN
          to_TO perform_VB 1000_CD Monte_NNP Carlo_NNP runs_VBZ for_IN the_DT docking_VBG ._. Both_DT
          ligand_NN and_CC the_DT target_NN protein_NN were_VBD kept_VBN rigid_JJ ._.
          Intermolecular_NNP energy_NN criteria_NNS were_VBD used_VBN to_TO identify_VB the_DT
          best_JJS possible_JJ dockings_NNS of_IN CTAP_NNP ._.
        
      
      
        Results_NNS
        
          Impaired_NNP infectivity_NN of_IN CAP_NNP treated_VBD HIV-_NNP 1_CD
          Results_NNS of_IN earlier_JJR studies_NNS indicated_VBD that_IN HIV-_NNP 1_CD
          infection_NN of_IN cells_NNS is_VBZ inhibited_VBD in_IN the_DT presence_NN of_IN CAP_NNP
          (_( ED_NNP 
          90_CD =_SYM 5_CD to_TO 10_CD μg_NN /_NN ml_NN for_IN HIV-_NNP 1_CD IIIB_NNP ,_,
          i_NNP ._. e_SYM ._. <_NN 200_CD nM_NN )_) [_NN 2_CD ]_NN ._. However_RB ,_, the_DT mechanism_NN involved_VBN
          in_IN the_DT inhibitory_NN activity_NN and_CC the_DT possibility_NN of_IN virus_NN
          inactivation_NN by_IN CAP_NNP have_VBP not_RB been_VBN explored_JJ ._. Results_NNS shown_VBN
          in_IN Fig_NNP ._. 1_LS indicate_VBP that_IN CAP_NNP in_IN a_DT dose_NN dependent_JJ manner_NN
          rapidly_RB inactivates_NNS at_IN 37_CD °_NN C_NNP HIV-_NNP 1_CD IIIB_NNP ,_, an_DT X_NNP 4_CD virus_NN and_CC
          HIV-_NNP 1_CD BaL_NNP ,_, an_DT R_NN 5_CD virus_NN ,_, the_DT latter_JJ appearing_VBG relatively_RB
          more_RBR resistant_JJ ._.
        
        
          CAP_NNP retention_NN on_IN the_DT surface_NN of_IN treated_VBN HIV-_NNP 1_CD
          particles_NNS
          Evidence_NN for_IN CAP-HIV-_NNP 1_CD binding_JJ was_VBD obtained_VBN from_IN
          results_NNS of_IN solid_JJ phase_NN immunoassays_NNS in_IN which_WDT attachment_NN
          of_IN HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP virus_NN particles_NNS ,_, respectively_RB
          (_( detected_VBN by_IN subsequent_JJ ELISA_NNP of_IN p_NN 24_CD antigen_NN released_VBN
          from_IN virus_NN particles_NNS by_IN detergent_NN treatment_NN )_) to_TO wells_NNS
          precoated_JJ with_IN CAP_NNP was_VBD measured_VBN (_( Fig_NNP ._. 2_LS A_DT )_) ._. CAP_NNP treated_VBD
          HIV-_NNP 1_CD IIIB_NNP and_CC BaL_NNP viruses_NNS ,_, unlike_IN control_NN viruses_NNS ,_, bound_VBN
          to_TO wells_NNS coated_VBN with_IN antibodies_NNS against_IN phthalate_NN (_( Fig_NNP ._.
          2_LS B_NNP )_) ._. These_DT results_NNS indicate_VBP that_WDT treated_VBD HIV-_NNP 1_CD particles_NNS ,_,
          utilizing_VBG either_CC CXCR_NNP 4_CD or_CC CCR_NNP 5_CD as_IN coreceptors_NNS ,_, retain_VB CAP_NNP
          on_IN their_PRP$ surface_NN and_CC suggest_VBP that_IN this_DT is_VBZ responsible_JJ for_IN
          the_DT altered_VBN properties_NNS and_CC impaired_VBN infectivity_NN of_IN the_DT
          treated_VBN viruses_NNS ._.
        
        
          Identification_NNP of_IN CAP_NNP binding_JJ sites_NNS on_IN HIV-_NNP 1_CD
          envelope_NN glycoproteins_NNS
          The_DT attachment_NN sites_NNS on_IN the_DT surface_NN of_IN HIV-_NNP 1_CD IIIB_NNP for_IN
          CAP_NNP were_VBD determined_VBN from_IN binding_JJ of_IN control_NN and_CC CAP_NNP
          treated_VBD HIV-_NNP 1_CD ,_, respectively_RB ,_, to_TO distinct_JJ ligands_NNS (_( Fig_NNP ._.
          3_LS )_) ._. The_DT quantities_NNS of_IN control_NN virus_NN and_CC treated_VBN virus_NN in_IN
          these_DT experiments_NNS were_VBD identical_JJ ,_, as_IN determined_VBN from_IN the_DT
          content_NN of_IN p_NN 24_CD antigen_NN in_IN preparations_NNS of_IN
          detergent-disrupted_JJ virus_NN particles_NNS ._. CAP_NNP binding_JJ to_TO HIV-_NNP 1_CD
          IIIB_NNP particles_NNS most_RBS profoundly_RB affected_VBN their_PRP$ binding_JJ to_TO
          the_DT V_NNP 3_CD loop_NN specific_JJ mAbs_NNS 9284_CD [_NN 26_CD ]_NN and_CC 9305_CD [_NN 27_CD ]_NN and_CC
          to_TO the_DT coreceptor_NN CXCR_NNP 4_CD ,_, while_IN binding_JJ to_TO sCD_NN 4_CD ;_: to_TO virus_NN
          neutralizing_VBG mAbs_NNS specific_JJ for_IN the_DT CD_NNP 4_CD binding_JJ site_NN on_IN
          gp_NN 120_CD ,_, b_SYM 12_CD [_NN 28_CD ]_NN and_CC 588_CD D_NNP [_NN 29_CD ]_NN ;_: to_TO mAb_NN 17_CD b_SYM specific_JJ
          for_IN a_DT discontinuous_JJ conserved_JJ epitope_NN proximal_NN to_TO the_DT
          binding_JJ site_NN for_IN both_DT CD_NNP 4_CD and_CC anti-_NN CD_NNP 4_CD binding_JJ site_NN
          antibodies_NNS [_NN 30_CD ]_NN ;_: to_TO mAb_NN 2_CD G_NNP 12_CD specific_JJ for_IN an_DT epitope_NN
          centered_VBN around_IN the_DT C_NNP 3_CD /_NN V_NNP 4_CD domain_NN of_IN gp_NN 120_CD also_RB involving_VBG
          N-_NNP linked_VBD glycans_NNS [_NN 31_CD ]_NN and_CC to_TO the_DT gp_NN 41_CD specific_JJ mAb_NN 2_CD F_NN 5_CD
          [_NN 32_CD ]_NN was_VBD less_RBR affected_JJ ._. In_IN order_NN to_TO determine_VB whether_IN
          R_NN 5_CD viruses_NNS are_VBP similarly_RB affected_VBN by_IN CAP_NNP ,_, the_DT binding_JJ of_IN
          HIV-_NNP 1_CD BaL_NNP as_IN a_DT representative_NN of_IN this_DT virus_NN group_NN to_TO
          anti-_NN V_NNP 3_CD BaL_NNP and_CC CCR_NNP 5_CD ,_, respectively_RB ,_, before_IN and_CC after_IN CAP_NNP
          treatment_NN was_VBD studied_VBN ._. The_DT results_NNS shown_VBN in_IN Fig_NNP ._.
          3_LS indicate_VBP that_IN the_DT CAP-treated_NNP HIV-_NNP 1_CD BaL_NNP bound_VBN to_TO these_DT
          ligands_NNS much_RB less_RBR than_IN did_VBD untreated_JJ virus_NN ._.
          The_DT binding_JJ of_IN control_NN and_CC CAP-treated_NNP HIV-_NNP 1_CD IIIB_NNP to_TO
          antibodies_NNS against_IN peptides_NNS derived_VBN from_IN gp_NN 120_CD /_NN gp_NN 41_CD [_NN 16_CD
          ]_NN was_VBD also_RB determined_VBN ._. In_IN agreement_NN with_IN the_DT results_NNS
          obtained_VBD using_VBG mAbs_NNS ,_, CAP_NNP treatment_NN resulted_VBD in_IN most_RBS
          pronounced_VBN decreases_NNS of_IN virus_NN binding_JJ to_TO antibodies_NNS
          against_IN peptide_NN 303_CD -_: 338_CD (_( =_SYM V_NNP 3_CD loop_NN )_) and_CC the_DT adjacent_JJ

          peptide_NN 280_CD -_: 306_CD (_( Fig_NNP ._. 4_LS )_) ._.
        
        
          Pretreatment_NNP with_IN CAP_NNP impairs_NNS gp_NN 120_CD binding_JJ to_TO
          coreceptors_NNS
          Data_NNP reported_VBD so_RB far_RB suggest_VBP that_IN the_DT lethal_JJ hit_NN to_TO
          HIV-_NNP 1_CD caused_VBN by_IN CAP_NNP treatment_NN involves_VBZ the_DT coreceptor_NN
          binding_JJ site_NN on_IN gp_NN 120_CD ._. To_TO further_VB support_NN this_DT
          conclusion_NN ,_, the_DT binding_JJ of_IN labeled_VBN gp_NN 120_CD -_: CD_NNP 4_CD complexes_NNS to_TO
          coreceptor_NN [_NN 11_CD 12_CD 33_CD ]_NN expressing_VBG cells_NNS was_VBD studied_VBN ._.
          First_LS ,_, it_PRP was_VBD determined_VBN from_IN quantitative_JJ binding_JJ
          studies_NNS using_VBG CAP_NNP staining_VBG with_IN ruthenium_NN red_JJ [_NN 21_CD ]_NN that_DT
          pretreatment_NN with_IN CAP_NNP resulted_VBD in_IN binding_JJ of_IN 0_CD ._. 90_CD ±_NN 0_CD ._. 13_CD
          CAP_NNP molecules_NNS /_NN gp_NN 120_CD in_IN TS_NNP ._. The_DT binding_JJ appeared_VBD augmented_JJ
          by_IN ~_NN 30_CD %_NN in_IN 1_CD M_NNP NaCl_NNP ._. The_DT binding_JJ capacity_NN of_IN gp_NN 120_CD for_IN
          sCD_NN 4_CD was_VBD preserved_VBN after_IN CAP_NNP treatment_NN (_( Fig_NNP ._. 5_LS )_) ._. On_IN the_DT
          other_JJ hand_NN ,_, gp_NN 120_CD -_: sCD_NN 4_CD complexes_NNS containing_VBG CAP_NNP treated_VBD
          gp_NN 120_CD bound_VBN to_TO coreceptor_NN expressing_VBG cells_NNS to_TO a_DT much_RB
          lesser_JJR extent_NN than_IN similar_JJ complexes_NNS containing_VBG untreated_JJ
          gp_NN 120_CD (_( Fig_NNP ._. 6_CD )_) ._.
        
      
      
        Discussion_NNP
        Negatively_NNP charged_VBD sulfated_JJ polymers_NNS were_VBD reported_VBN to_TO
        have_VB anti-_NN HIV-_NNP 1_CD activity_NN and_CC are_VBP being_VBG considered_VBN for_IN
        development_NN as_IN topical_JJ microbicides_NNS ._. They_PRP include_VBP :_: dextran_NN
        sulfate_NN [_NN 34_CD 35_CD ]_NN ,_, carrageenans_NNS [_NN 35_CD 36_CD ]_NN ,_,
        dextrin-_NN 2_CD -_: sulfate_NN [_NN 37_CD 38_CD ]_NN ,_, cellulose_NN sulfate_NN [_NN 39_CD ]_NN and_CC
        naphthalene_NN sulfonate_NN polymer_NN (_( PRO_FW 2000_CD ;_: [_NN 40_CD ]_NN )_) ._. Except_IN
        for_IN dextrin-_NN 2_CD -_: sulfate_NN and_CC PRO_FW 2000_CD ,_, which_WDT appear_VBP to_TO have_VB
        anti-_NN HIV-_NNP 1_CD inhibitory_NN activities_NNS similar_JJ to_TO that_DT of_IN CAP_NNP ,_,
        the_DT other_JJ sulfonated_JJ polymers_NNS are_VBP less_JJR inhibitory_NN [_NN 34_CD 35_CD
        41_CD ]_NN ._. HIV-_NNP 1_CD may_MD develop_VB resistance_NN to_TO the_DT inhibitory_NN
        effect_NN of_IN dextran_NN sulfate_NN and_CC R_NN 5_CD viruses_NNS were_VBD reported_VBN not_RB
        to_TO be_VB inhibited_VBD by_IN this_DT polymer_NN [_NN 42_CD 43_CD ]_NN ._. Dextran_NNP sulfate_NN
        was_VBD shown_VBN to_TO bind_NN to_TO gp_NN 120_CD and_CC to_TO interfere_VB with_IN
        gp_NN 120_CD /_NN CXCR_NNP 4_CD interactions_NNS but_CC it_PRP did_VBD not_RB bind_NN to_TO gp_NN 120_CD of_IN R_NN 5_CD
        viruses_NNS [_NN 43_CD ]_NN ._.
        CAP_NNP in_IN micronized_JJ form_NN ,_, providing_VBG an_DT acidic_JJ environment_NN ,_,
        causes_NNS disintegration_NN of_IN HIV-_NNP 1_CD leading_VBG to_TO loss_NN of_IN
        infectivity_NN (_( 2_LS )_) ._. Here_RB we_PRP have_VBP shown_VBN that_IN CAP_NNP directly_RB
        inactivates_NNS HIV-_NNP 1_CD at_IN neutral_JJ pH_NN since_IN treated_VBN virus_NN
        particles_NNS after_IN removal_NN of_IN excess_JJ CAP_NNP had_VBD reduced_VBN or_CC no_DT
        infectivity_NN (_( Fig_NNP ._. 1_LS )_) ,_, in_IN agreement_NN with_IN recent_JJ observations_NNS
        [_NN 44_CD 45_CD ]_NN ._. Virus_NNP inactivation_NN can_MD be_VB attributed_VBN to_TO strong_JJ
        binding_JJ of_IN CAP_NNP to_TO HIV-_NNP 1_CD ,_, preventing_VBG the_DT access_NN to_TO virus_NN
        particles_NNS predominantly_RB of_IN antibodies_NNS against_IN the_DT gp_NN 120_CD V_NNP 3_CD
        loop_NN ,_, known_VBN to_TO be_VB involved_VBN in_IN coreceptor_NN binding_JJ and_CC
        specificity_NN [_NN 15_CD 46_CD 47_CD 48_CD 49_CD ]_NN ,_, and_CC to_TO epitopes_NNS located_VBN
        adjacent_JJ to_TO the_DT V_NNP 3_CD loop_NN (_( Fig_NNP ._. 4_LS )_) ._. Indeed_RB ,_, CAP_NNP binding_JJ to_TO
        HIV-_NNP 1_CD resulted_VBD in_IN blockade_NN of_IN sites_NNS involved_VBN in_IN coreceptor_NN
        binding_JJ (_( Fig_NNP ._. 3_LS )_) ._. This_DT was_VBD observed_VBN for_IN both_DT HIV-_NNP 1_CD IIIB_NNP ,_, an_DT
        X_NNP 4_CD virus_NN ,_, and_CC HIV-_NNP 1_CD BaL_NNP ,_, an_DT R_NN 5_CD virus_NN ._. In_IN agreement_NN with_IN
        this_DT finding_NN ,_, CAP_NNP inhibited_VBD infection_NN by_IN both_DT X_NNP 4_CD and_CC R_NN 5_CD
        viruses_NNS in_IN 
        in_IN vitro_NN models_NNS for_IN vaginal_JJ HIV-_NNP 1_CD
        infection_NN [_NN 45_CD 50_CD ]_NN ._. Sites_NNP on_IN the_DT HIV-_NNP 1_CD envelope_NN other_JJ
        than_IN the_DT coreceptor_NN binding_JJ domains_NNS may_MD possibly_RB be_VB also_RB
        involved_VBN in_IN interactions_NNS with_IN CAP_NNP ,_, contributing_VBG to_TO
        inhibition_NN of_IN virus_NN infection_NN ._.
        Studies_NNS with_IN gp_NN 120_CD allowed_VBN to_TO determine_VB the_DT
        stoichiometry_NN of_IN the_DT reaction_NN between_IN gp_NN 120_CD and_CC CAP_NNP ,_,
        resulting_VBG in_IN the_DT observation_NN that_IN approximately_RB one_CD CAP_NNP
        molecule_NN binds_NNS to_TO one_CD molecule_NN of_IN gp_NN 120_CD ._. Interestingly_RB ,_,
        CAP-gp_NNP 120_CD binding_JJ also_RB occurs_VBZ in_IN 1_CD M_NNP NaCl_NNP ,_, conditions_NNS under_IN
        which_WDT binding_JJ of_IN sulfated_JJ polysaccharides_NNS to_TO gp_NN 120_CD is_VBZ
        abolished_VBN [_NN 43_CD ]_NN ._. This_DT suggests_VBZ that_IN electrostatic_JJ
        interactions_NNS do_VBP not_RB play_VB an_DT exclusive_JJ role_NN in_IN CAP-gp_NNP 120_CD
        binding_JJ [_NN 51_CD ]_NN ._.
        Since_IN CAP_NNP has_VBZ an_DT approximate_JJ M_NNP 
        w_NN of_IN 6_CD ×_NN 10_CD 4_CD and_CC its_PRP$ structure_NN has_VBZ not_RB
        been_VBN determined_VBN ,_, a_DT model_NN for_IN CAP_NNP docking_VBG onto_IN gp_NN 120_CD (_( HXBc_NNP 2_LS )_)
        was_VBD generated_VBN using_VBG a_DT chemically_RB modified_VBN cellotetraose_NN ._.
        The_DT entire_JJ gp_NN 120_CD surface_NN was_VBD considered_VBN for_IN docking_VBG
        acetylated_JJ and_CC phthaloylated_JJ cellotetraose_NN (_( CTAP_NNP )_) except_IN
        the_DT trimerization_NN and_CC CD_NNP 4_CD binding_JJ sites_NNS on_IN gp_NN 120_CD [_NN 13_CD ]_NN ._.
        The_DT two_CD optimally_RB docked_JJ CTAP_NNP molecules_NNS were_VBD selected_VBN for_IN
        further_JJ analyses_NNS ._. The_DT first_JJ one_CD (_( marked_VBD as_IN 
        Dock_NNP 1_CD in_IN Fig_NNP ._. 7_CD )_) docked_JJ near_IN regions_NNS
        corresponding_JJ to_TO amino_JJ acid_NN residues_NNS 361_CD -_: 392_CD (_( indicated_VBD in_IN
        red_JJ )_) and_CC 386_CD -_: 417_CD (_( indicated_VBD in_IN purple_JJ )_) ._. The_DT orientation_NN of_IN
        CTAP_NNP revealed_VBD that_IN if_IN extended_VBN to_TO generate_VB the_DT larger_JJR CAP_NNP
        molecule_NN ,_, blockade_NN of_IN the_DT coreceptor_NN binding_JJ site_NN
        (_( indicated_VBD in_IN gray_JJ in_IN Fig_NNP ._. 7_CD )_) [_NN 15_CD ]_NN and_CC the_DT V_NNP 3_CD loop_NN
        (_( indicated_VBD in_IN yellow_JJ in_IN Fig_NNP ._. 7_CD )_) would_MD result_VB ._. These_DT docking_VBG
        results_NNS agree_VBP with_IN the_DT observation_NN that_WDT capture_NN of_IN CAP_NNP
        treated_VBD HIV-_NNP 1_CD virions_NNS to_TO antibodies_NNS against_IN peptides_NNS from_IN
        these_DT regions_NNS (_( 303_CD -_: 338_CD ,_, 361_CD -_: 392_CD ,_, 386_CD -_: 417_CD )_) was_VBD decreased_VBN
        (_( Fig_NNP ._. 4_LS )_) ._. CTAP_NNP interacts_NNS primarily_RB through_IN several_JJ hydrogen_NN
        bonds_NNS with_IN gp_NN 120_CD residues_NNS K_NNP 362_CD ,_, N_NNP 386_CD ,_, Q_NNP 389_CD ,_, N_NNP 392_CD and_CC T_NN 394_CD ._.
        Though_IN there_EX were_VBD no_DT hydrophobic_JJ or_CC electrostatic_JJ
        interactions_NNS discernable_JJ ,_, such_JJ interactions_NNS cannot_NN be_VB ruled_VBN
        out_IN as_IN CTAP_NNP represents_VBZ only_RB a_DT small_JJ part_NN of_IN the_DT CAP_NNP
        molecule_NN ._. The_DT second_JJ best_JJS docking_VBG positioned_VBN CTAP_NNP near_IN the_DT
        V_NNP 3_CD loop_NN (_( marked_VBD as_IN 
        Dock_NNP 2_CD in_IN Fig_NNP ._. 7_CD )_) ._. CTAP_NNP in_IN this_DT
        position_NN interacts_NNS with_IN gp_NN 120_CD through_IN both_DT hydrogen_NN bonding_NN
        (_( residues_NNS R_NN 311_CD and_CC R_NN 315_CD )_) and_CC hydrophobic_JJ forces_NNS (_( F_NN 317_CD )_) with_IN
        two_CD CH_NNP 
        3_CD CO-_NNP units_NNS of_IN CTAP_NNP ._. The_DT interacting_VBG
        region_NN is_VBZ in_IN the_DT RGPGRAF_NNP principal_JJ neutralizing_VBG domain_NN
        (_( PND_NNP )_) of_IN the_DT V_NNP 3_CD loop_NN [_NN 52_CD ]_NN ._. Both_DT R_NN 311_CD and_CC R_NN 315_CD residues_NNS
        are_VBP also_RB in_IN close_JJ proximity_NN to_TO two_CD acid_NN groups_NNS of_IN the_DT CTAP_NNP
        phthalic_JJ acid_NN moiety_NN and_CC may_MD take_VB part_NN in_IN electrostatic_JJ
        interactions_NNS ._. Although_IN CTAP_NNP is_VBZ only_RB a_DT partial_JJ
        representation_NN of_IN the_DT CAP_NNP molecule_NN ,_, the_DT docking_VBG simulations_NNS
        agree_VBP with_IN the_DT experimental_JJ results_NNS ._.
        Results_NNS presented_VBN earlier_JJR [_NN 2_CD ]_NN combined_VBN with_IN those_DT
        presented_VBN here_RB suggest_VBP that_IN CAP_NNP acts_NNS on_IN HIV-_NNP 1_CD by_IN several_JJ
        mechanisms_NNS ,_, depending_VBG on_IN pH_NN and_CC the_DT physical_JJ form_NN and_CC
        concentration_NN of_IN this_DT compound_NN ._. The_DT direct_JJ virus_NN
        inactivating_VBG effect_NN of_IN CAP_NNP ,_, the_DT multiple_JJ mechanisms_NNS
        involved_VBN in_IN prevention_NN of_IN HIV-_NNP 1_CD infection_NN ,_, the_DT broad_JJ
        spectrum_NN activity_NN against_IN several_JJ STD_NNP pathogens_NNS ,_, the_DT
        established_VBN safety_NN record_NN ,_, low_JJ cost_NN and_CC availability_NN in_IN
        large_JJ scale_NN suggest_VBP that_IN CAP_NNP has_VBZ advantages_NNS over_IN other_JJ
        polymeric_JJ substances_NNS considered_VBN as_IN topical_JJ (_( vaginal_JJ )_)
        microbicides_NNS for_IN prevention_NN of_IN STDs_NNP ,_, including_VBG AIDS_NNP ._.
      
      
        Conclusions_NNP
        Cellulose_NNP acetate_NN phthalate_NN (_( CAP_NNP )_) is_VBZ a_DT pharmaceutical_JJ
        excipient_NN which_WDT has_VBZ been_VBN used_VBN for_IN over_IN four_CD decades_NNS for_IN
        enteric_JJ film_NN coating_NN of_IN tablets_NNS and_CC capsules_NNS ._. It_PRP is_VBZ
        inexpensive_JJ and_CC generally_RB regarded_VBN as_IN a_DT nontoxic_JJ material_NN
        free_JJ of_IN adverse_JJ effects_NNS ._. As_IN such_JJ ,_, it_PRP is_VBZ included_VBN in_IN the_DT US_NNP
        Food_NNP and_CC Drug_NNP Administration_NNP Inactive_NNP Ingredients_NNP Guide_NNP ._.
        Our_PRP$ earlier_JJR studies_NNS indicated_VBD that_IN CAP_NNP inhibited_VBD infection_NN
        by_IN HIV-_NNP 1_CD and_CC several_JJ herpes_NNS viruses_NNS in_IN vitro_NN ._. CAP_NNP was_VBD
        effective_JJ in_IN blocking_VBG vaginal_JJ transmission_NN of_IN these_DT viruses_NNS
        in_IN animal_NN model_NN systems_NNS ._. The_DT underlying_VBG molecular_JJ
        machanisms_NNS for_IN these_DT inhibitory_NN effects_NNS remained_VBD to_TO be_VB
        established_VBN ._. Data_NNP presented_VBD here_RB show_NN that_IN CAP_NNP remains_VBZ
        bound_VBN to_TO HIV-_NNP 1_CD after_IN removal_NN of_IN unreacted_JJ compound_NN ,_,
        impairing_VBG virus_NN infectivity_NN due_JJ to_TO blockade_NN of_IN binding_JJ
        sites_NNS for_IN cellular_JJ coreceptors_NNS CXCR_NNP 4_CD and_CC CCR_NNP 5_CD ._. The_DT
        industrial_JJ availability_NN ,_, history_NN of_IN safe_JJ use_NN and_CC mechanism_NN
        of_IN anti-_NN HIV-_NNP 1_CD activity_NN (_( i_NNP ._. e_SYM ._. virus_NN inactivation_NN rather_RB than_IN
        reversible_JJ inhibition_NN )_) suggest_VBP that_IN CAP_NNP is_VBZ an_DT ideal_JJ
        candidate_NN compound_NN for_IN a_DT vaginal_JJ microbicide_NN expected_VBN to_TO
        prevent_VB sexual_JJ transmission_NN of_IN HIV-_NNP 1_CD ._.
      
      
        List_NN of_IN Abbreviations_NNP used_VBD
        CAP_NNP ,_, cellulose_NN acetate_NN phthalate_NN ;_: STD_NNP ,_, sexually_RB
        transmitted_VBD disease_NN ;_: ELISA_NNP ,_, enzyme-linked_JJ immunosorbent_NN
        assay_NN ;_: mAbs_NNS ,_, monoclonal_NN antibodies_NNS ;_: FBS_NNP ,_, fetal_JJ bovine_JJ
        serum_NN ;_: PEG_NNP 6000_CD ,_, polyethylene_NN glycol_NN 6000_CD ;_: HIV-_NNP 1_CD ,_, human_JJ
        immunodeficiency_NN virus_NN type_NN 1_CD ;_: SIV_NNP ,_, simian_NN immunodeficiency_NN
        virus_NN ;_: HSV-_NNP 1_CD ,_, herpesvirus_JJ type_NN 1_CD ;_: HSV-_NNP 2_CD ,_, herpesvirus_JJ type_NN
        2_CD ;_: BSA_NNP ,_, bovine_JJ serum_NN albumin_NN ;_: PBS_NNP ,_, phosphate_NN buffered_JJ
        saline_NN ;_: HRP_NNP ,_, horse_NN radish_NN peroxidase_NN ;_: sCD_NN 4_CD ,_, soluble_JJ CD_NNP 4_CD ;_:
        TS_NNP ,_, 0_CD ._. 14_CD M_NNP NaCl_NNP ,_, 0_CD ._. 01_CD M_NNP Tris_NNP ,_, pH_NN 7_CD ._. 0_CD ;_: PBL_NNP ,_, peripheral_JJ blood_NN
        lymphocytes_NNS ;_: CTAP_NNP ,_, cellotetraose_NN acetate_NN phthalate_NN ;_: pdb_NN ._.
        Protein_NNP Data_NNP Bank_NNP ._.
      
      
        Declaration_NNP of_IN Competing_VBG Interests_NNP
        None_NN declared_VBD
      
    
  
